Since 1923, we have been focused on innovation and leadership in diabetes care. Today we have a broad portfolio of medicines.
Since the launch of our first pen needle in 1985, we have been committed to enhancing injection experience by putting technology in patient hands.
Access information on our products for rare bleeding disorders, growth hormone-related disorders, and women's health.
Find information on our treatment for chronic weight management in adults who are overweight with one weight-related comorbidity or obesity.
The link above used in conjunction with the FDA-approved product labeling may be used to determine U.S. patents associated with the corresponding U.S. marketed product.
Novo Nordisk CMO Dr. Todd Hobbs answers questions about managing your health as the pandemic continues.
View the video series
Need help affording your
us help. Visit
NovoCare.com or Call 1.844.NOVO4ME (1.844.688.6463)
Nordisk Inc. COVID-19 Information and Resources
all press releases
All personal information reported in relation to a complaint or a
side effect will be processed in accordance with applicable data
protection legislation. For avoidance of doubt, “data protection
legislation” means the law governing the Novo Nordisk entity receiving
the complaint or report, not the residence or location of the
individual data subject submitting the report or complaint: